The global Medical Devices Electronics Manufacturing Services (EMS) market is projected to grow from USD 15.1 billion in 2024 to USD 20.59 billion by 2031, at a compound annual growth rate (CAGR) of 4.6%. This growth is driven by increasing demand for connected healthcare, device miniaturization, automation, and regional production diversification. Key players including Foxconn, Jabil, Flex, Sanmina, and Celestica are leading innovation in AI-powered medical devices, wearable health monitors, and digital twin hospital platforms. The market is shifting toward end-to-end EMS solutions, with a strong focus on engineering services, testing, and compliance. Regional dynamics show Asia-Pacific as the largest and fastest-growing region, with China maintaining dominance in production. Regulatory compliance, particularly with ISO 13485 and FDA standards, is shaping strategic decisions. In 2025, several mid-sized EMS firms are undergoing strategic acquisitions or forming joint ventures to expand capacity in diagnostics and treatment equipment.

The global gesture recognition market reached $21.33 billion in 2024 and is projected to grow to $66.72 billion by 2032, with a compound annual growth rate (CAGR) of 15.32% from 2025 to 2032. Growth is driven by increasing adoption of touchless interfaces in consumer electronics, automotive, healthcare, and other sectors, fueled by advancements in AI and sensor technologies, rising demand for enhanced user experiences, and a growing emphasis on hygiene and safety. A Paris-based AI startup, Veesion, has developed a gesture recognition system that uses existing store cameras to detect suspicious customer behavior and alert store staff, currently deployed in thousands of stores including in the USA and expanding across North America. While no specific Japan-related updates were reported in the past three months, broader trends in AR, AI interfaces, and wearable tech indicate continued innovation in Japan and globally. Key players include Intel Corporation, Jabil Inc., Microchip Technology Inc., Sony Corporation, Ultraleap, Elliptic Laboratories AS, Google LLC, GestureTek Inc., Nice - Polska Sp.z o.o., and Dreamworth Solutions Pvt. Ltd. The market report, published by DataM Intelligence, provides comprehensive analysis through qualitative and quantitative research, covering market trends, segmentation, regional dynamics, and strategic insights.

The global contract manufacturing market is projected to grow from $686.4 billion in 2025 to $968.7 billion by 2030, at a compound annual growth rate (CAGR) of 7.1%. This growth is driven by rising demand for outsourcing, expansion in consumer electronics, technological advances such as automation and AI, increased healthcare infrastructure investment, and stronger collaborations between pharmaceutical companies and contract manufacturers. The Asia-Pacific region led the market in 2024 with a 38.4% share and is expected to reach $354.4 billion by 2030. The report analyzes market segments by contract type, distribution channel, and end-use industry, with consumer electronics expected to dominate through 2030. It also highlights emerging startups like Mefron, IndyGeneUS Bio, and AtomVie, and profiles major industry players including Flex Ltd., Jabil Inc., and HON HAI Precision Industry Co. Ltd.

The global autoinjectors market is projected to grow from US$1.40 billion in 2024 to US$3.02 billion by 2030, at a CAGR of 13.6%, driven by technological advancements, rising chronic disease prevalence, and increased adoption of biologics and smart devices. The autoinjector finished formulations market is expected to reach USD 134.27 billion in 2030, growing at a CAGR of 12.2%. Key growth factors include ease of use, biologics pipeline expansions, and integration of connectivity features such as Bluetooth and dose monitoring. Subcutaneous administration dominates, with obesity management emerging as a high-growth therapy area due to FDA-approved treatments like Wegovy. North America leads the market, while Asia Pacific is expected to see significant growth. Major players include Becton, Dickinson and Company, Ypsomed Holding AG, SHL Medical AG, West Pharmaceutical Services, Inc., Recipharm AB, AbbVie Inc., Eli Lilly and Company, Amgen Inc., Novo Nordisk A/S, Johnson & Johnson, Sanofi, and GSK plc. Market trends point toward next-generation smart autoinjectors and expanded access in high-growth regions.

In the first quarter of 2025, several institutional investors and hedge funds increased their holdings in Jabil, Inc. (NYSE:JBL), with LPL Financial LLC raising its position by 12.6% to 45,878 shares valued at $6.243 million. Other notable investors including Zurcher Kantonalbank Zurich Cantonalbank, Spectrum Wealth Counsel LLC, Empirical Finance LLC, TD Asset Management Inc, and HB Wealth Management LLC also increased their stakes. The company reported strong quarterly earnings, with $2.55 earnings per share and $7.83 billion in revenue, exceeding analyst expectations. Analysts have upgraded Jabil’s stock rating, with Argus, JPMorgan Chase & Co., Bank of America, UBS Group, and Raymond James Financial adjusting their ratings and target prices. The stock currently has an average rating of 'Buy' and an average price target of $231.71. Jabil announced a dividend of $0.08 per share, payable on September 3rd, with a dividend yield of 14.0%. Insiders, including EVP Andrew Priestley and Director Anousheh Ansari, sold shares in July, resulting in a net decrease in their ownership. The company has a market capitalization of $23.87 billion and operates in electronics and diversified manufacturing services.